Complement activation via alternative pathway is critical in the development of laser-induced choroidal neovascularization: Role of factor B and factor H

被引:109
作者
Bora, Nalini S.
Kaliappan, Sankaranarayanan
Jha, Purushottam
Xu, Qin
Sohn, Jeong-Hyeon
Dhaulakhandi, Dhara B.
Kaplan, Henry J.
Bora, Puran S.
机构
[1] Univ Arkansas Med Sci, Jones Eye Inst, Dept Ophthalmol, Pat & Willard Walker Eye Res Ctr, Little Rock, AR 72205 USA
[2] Univ Louisville, Dept Ophthalmol & Visual Sci, Kentucky Lions Eye Ctr, Louisville, KY 40202 USA
关键词
D O I
10.4049/jimmunol.177.3.1872
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The objective of this study was to explore the role of classical, lectin, and alternative pathways of complement activation in laser-induced choroidal neovascularization (CNV). The classical and alternative pathways were blocked in C57BL/6 mice by small interfering RNAs (siRNA) directed against C1q and factor B, respectively. C4(-/-) mice developed CNV similar to their wild-type controls and inhibition of C1q by ARNA had no effect on the, development of CNV. In contrast, CNV was significantly inhibited (p < 0.001) in C5(-/-) mice and C57BL/6 mice treated with factor B ARNA. Inhibition of the alternative pathway by factor B ARNA resulted in decreased levels of membrane attack complex and angiogenic factors-vascular endothelial growth factor and TGF-beta 2. Furthermore, factor B was up-regulated in complement sufficient C57BL/6 mice at day 1 postlaser and remained elevated at day 7. Significantly reduced levels of factor H were observed at day 3 in these animals. In conclusion, our results demonstrate that activation of the factor B-dependent alternative pathway, but not the classical or lectin pathways, was essential for the development of CNV in mouse model of laser-induced CNV. Thus, specific blockade of the alternative pathway may represent a therapeutically relevant strategy for the inhibition of CNV.
引用
收藏
页码:1872 / 1878
页数:7
相关论文
共 39 条
  • [31] Immunological and aetiological aspects of macular degeneration
    Penfold, PL
    Madigan, MC
    Gillies, MC
    Provis, JM
    [J]. PROGRESS IN RETINAL AND EYE RESEARCH, 2001, 20 (03) : 385 - 414
  • [32] Reich S, 2003, MOL VIS, V9, P210
  • [33] Samano Eliana Sueco Tibana, 2004, Rev. Hosp. Clin., V59, P138, DOI 10.1590/S0041-87812004000300009
  • [34] RNAi: gene-silencing in therapeutic intervention
    Shuey, DJ
    McCallus, DE
    Giordano, T
    [J]. DRUG DISCOVERY TODAY, 2002, 7 (20) : 1040 - 1046
  • [35] Proteases of the complement system
    Sim, RB
    Tsiftsoglou, SA
    [J]. BIOCHEMICAL SOCIETY TRANSACTIONS, 2004, 32 : 21 - 27
  • [36] COMPLEMENT DEFENSE-MECHANISMS
    TOMLINSON, S
    [J]. CURRENT OPINION IN IMMUNOLOGY, 1993, 5 (01) : 83 - 89
  • [37] Genetic susceptibility to age related macular degeneration
    Yates, JRW
    Moore, AT
    [J]. JOURNAL OF MEDICAL GENETICS, 2000, 37 (02) : 83 - 87
  • [38] Vascular endothelial growth factor expression in choroidal neovascularization in rats
    Yi, XJ
    Ogata, N
    Komada, M
    Yamamoto, C
    Takahashi, K
    Omori, K
    Uyama, M
    [J]. GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 1997, 235 (05) : 313 - 319
  • [39] Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer
    Zhang, Y
    Zhang, YF
    Bryant, J
    Charles, A
    Boado, RJ
    Pardridge, WM
    [J]. CLINICAL CANCER RESEARCH, 2004, 10 (11) : 3667 - 3677